



**2023**  
**GUIDELINES**  
**Annual Report**

**ASCO**<sup>®</sup>  
AMERICAN SOCIETY OF CLINICAL ONCOLOGY  
KNOWLEDGE CONQUERS CANCER

# TABLE OF CONTENTS

---

2023 Guidelines Overview	3
Journals	5
Website Analytics	6
Cancer.Net	7
Social Media Statistics	8
Guidelines Clinical Tools and Resources	9
ASCO Guidelines Podcast Series	12
Current Guidelines Landscape	15
Collaborating Organizations	26
Cancer Journey Tables	27

---

## 2023 Guidelines Overview

### Guidelines Publications by Disease Site

#### Breast

- Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update

#### Gastrointestinal

- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Q and A
- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
- Systemic Therapy for Tumor Control in Well-differentiated Metastatic Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Q and A

#### Genitourinary

- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&A
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A
- Penile Cancer: EAU-ASCO Collaborative Guidelines -2023 Update
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update: ASCO Guideline Q and A
- Systemic Therapy for Tumor Control in Well-differentiated Metastatic Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Q and A
- Penile Cancer: EAU-ASCO Collaborative Guidelines Update Q and A
- Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update

#### Head and Neck

- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A

#### Melanoma

- Systemic Therapy for Melanoma: ASCO Guideline Update
- Systemic Therapy for Melanoma: ASCO Guideline Update Q and A

### **Survivorship**

- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update Q&A
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline Summary and Q&A
- Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments

### **Supportive Care**

- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update
- Cancer Cachexia: ASCO Guideline Rapid Recommendation
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Q and A

### **Thoracic**

- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.3
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.2
- Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update
- Systemic Therapy for SCLC: ASCO-Ontario Health (Cancer Care Ontario) Guideline

<b>Guideline Publication Number Breakdown</b>	
<b>Number of De Novo Guidelines</b>	11
<b>Number of Updates</b>	6
<b>Number of Rapid Updates</b>	6
<b>Number of Q&amp;As</b>	12

Journals Publications Breakdown	
Journal of Clinical Oncology (JCO)	23
Journal of Oncology Practice (JOP)	13

## Journals

### Top 10 Most Viewed JCO Articles

- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
- Systemic Therapy for Melanoma: ASCO Guideline Update
- Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

### Top 10 Most Viewed JCO OP Articles


- Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Q and A
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline Q&A
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Questions and Answers
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update: ASCO Guideline Q and A
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
- Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments

- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: SIO-ASCO Guideline Summary and Q&A
- Systemic Therapy for Tumor Control in Well-Differentiated Metastatic Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline Q and A
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update Q&A
- Systemic Therapy for Melanoma: ASCO Guideline Update Q and A

## Website Analytics (ASCO.org)

### Page Views, Visits, and Unique Visitors by Month

	Page Views	Visits	Unique Visitors
January	53,087	14,048	11,429
February	43,856	12,375	10,057
March	50,558	14,803	11,853
April	45,863	13,280	10,803
May	51,868	14,291	11,561
June	46,556	14,175	11,684
July	43,795	12,609	10,224
August	42,917	13,024	10,600
September	40,591	12,118	9,917
October	48,755	13,510	11,063
November	40,360	13,648	11,063
December	27,547	8,359	6,916
<b>Total</b>	<b>535,753</b>	<b>156,236</b>	<b>116,712</b>



**Top 10 Pages Viewed in 2023**

	Page Views	Visit	Unique Visitors
ASCO: Practice & Patients>Breast Cancer	73,536	38,797	28,778
ASCO: Practice & Patients>Guidelines, Tools, & Resources	66,112	48,855	37,415
ASCO: Practice & Patients>Supportive Care and Treatment-Related Issues	41,760	27,253	22,092
ASCO: Practice & Patients>Gastrointestinal Cancer	27,171	15,599	12,149
ASCO: Practice & Patients>Thoracic Cancer	21,975	12,315	8,798
ASCO: Practice & Patients>Genitourinary Cancer	19,859	11,897	8,789
ASCO: Practice & Patients>Patient and Survivor Care	14,274	10,123	7,992
ASCO: Practice & Patients>Gynecologic Cancer	11,592	7,201	5,515
ASCO: Practice & Patients>Head and Neck Cancer	11,351	7,074	5,314

**Cancer.Net**

ASCO Guidelines content is included on Cancer.Net as standalone articles or incorporated into Cancer.Net publications. In 2023, guidelines-related content received over **2.6 million page views**.

**Top 5 Most Viewed Cancer.Net Content by Cancer Type in 2023**

Cancer Type	Guideline	Cancer.Net Content	Page Views
Prostate Cancer	Active Surveillance of Localized Prostate Cancer	Prostate Cancer - Types of Treatment	173,610

Breast Cancer	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update	Breast Cancer - Types of Treatment	97,954
Lung Cancer - Non-Small Cell	Systemic Therapy for Stage IV NSCLC without Driver Alterations	Lung Cancer - Non-Small Cell - Types of Treatment	55,737
Breast Cancer - Metastatic	Systemic Therapy for Patients With Advanced HER2-positive Breast Cancer	Breast Cancer - Metastatic - Types of Treatment	39,516
Melanoma	Systemic Therapy for Melanoma	Melanoma - Types of Treatment	30,917

## Social Media Statistics

### Facebook

Shares	Likes	Link clicks	Impressions
136	698	602	73,374

### Twitter

Shares	Likes	Link Clicks	Impressions
286	586	801	328,724

### Most Popular Tweets (By Impressions)

Content Summary	Likes	Shares	Link Clicks	Impressions
Management of Stage III NSCLC Rapid Recommendation Update	65	36	102	70,921
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy	56	36	86	28,487



Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer	36	19	39	17,901
Management of Cancer Cachexia	78	42	46	13,237
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer	48	16	50	13,105
Management of Stage III Non-Small Cell Lung Cancer	9	10	29	11,264
Systemic Therapy Update on <sup>177</sup> Lutetium-PSMA-617 For Metastatic Castration-Resistant Prostate Cancer Rapid Recommendation Update	9	4	23	10,471
Management of Anxiety and Depression in Adult Survivors of Cancer	40	22	16	9,056
Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer	13	4	29	9,041

## Guidelines Clinical Tools and Resources

**Total Tools: 93**

### Summary of Recommendations Tables: 21

- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Penile Cancer: EAU-ASCO Collaborative Guidelines -2023 Update
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update
- Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update

- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
- Cancer Cachexia: ASCO Guideline Rapid Recommendation Update
- Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline
- Systemic Therapy for Melanoma: ASCO Guideline Update
- Systemic Therapy for SCLC: ASCO-Ontario Health (Cancer Care Ontario) Guideline
- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
- Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update
- Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update

#### **Slide Sets: 21**

- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Penile Cancer: EAU-ASCO Collaborative Guidelines -2023 Update
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update
- Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
- Cancer Cachexia: ASCO Guideline Rapid Recommendation Update
- Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline
- Systemic Therapy for Melanoma: ASCO Guideline Update
- Systemic Therapy for SCLC: ASCO-Ontario Health (Cancer Care Ontario) Guideline

- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
- Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update
- Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update


#### **Visual Abstracts/Graphics: 21**

- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Penile Cancer: EAU-ASCO Collaborative Guidelines -2023 Update
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update
- Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
- Cancer Cachexia: ASCO Guideline Rapid Recommendation Update
- Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline
- Systemic Therapy for Melanoma: ASCO Guideline Update
- Systemic Therapy for SCLC: ASCO-Ontario Health (Cancer Care Ontario) Guideline
- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline
- Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update
- Systemic Therapy for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update

#### **Algorithms & Flow Charts: 30**

- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline (1)

- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.1 (3)
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.1 (2)
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update (1)
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (4)
- Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update (1)
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update (6)
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.2 (3)
- Management of Stage III NSCLC: ASCO Guideline Rapid Recommendation Update (2)
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline (2)
- Systemic Therapy for Melanoma: ASCO Guideline Update (1)
- Systemic Therapy for SCLC: ASCO-Ontario Health (Cancer Care Ontario) Guideline (3)
- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline (1)



## ASCO Guidelines Podcast Series

**Episodes Released in 2023:** 21

**Unique Downloads in 2023:** 108,325

**IAB Downloads in 2023:** 94,785

**Total Unique Downloads All-Time:** 402,453


**Total IAB Downloads (starting 7/12/19):** 331,979

### Feedback

Apple Podcasts: 4.6 out of 5 stars (42 ratings)

Spotify: 5.0 out of 5 stars (2 ratings)

2023 Monthly Downloads		
Month	# of Unique Downloads	# of Episodes Released
January	11,072	3
February	6,125	0
March	8,362	1
April	13,697	5
May	7,756	1
June	8,299	1
July	13,948	4
August	11,616	1
September	9,514	2
October	9,580	2
November	5,885	1
December	2,471	0




**Top Downloaded Episodes in 2023:**

1. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Rapid Recommendation Update: **3,807 downloads** released 1/20/23
2. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of CAP Guideline: **3,641 downloads** released 1/6/23
3. HER2 Testing In Breast Cancer: ASCO-CAP Guideline Update: **3,291 downloads** released 6/7/23
4. VTE Prophylaxis and Treatment in Patients with Cancer Guideline Update: **3,284 downloads** released 4/19/23
5. Targeted Therapy and Immunotherapy for Gastroesophageal Cancer Guideline: **3,195 downloads** released 1/5/23

**Yearly Unique Downloads**

- **2018:** 14,988
- **2019:** 37,742
- **2020:** 51,415
- **2021:** 71,137
- **2022:** 118,846
- **2023:** 108,322



#### Average # of Downloads of a New Episode in the First 30 Days

- **2018:** 345
- **2019:** 969.32
- **2020:** 1050.76
- **2021:** 1053.03
- **2022:** 1442.64
- **2023:** 1619.67

#### The Difference Between IAB and Unique Downloads

IAB: is an acronym for the “Interactive Advertising Bureau” – an organization that has developed a series of industry standards to define what counts as a download.

The IAB-certified metric applies the following filters:

- Applying IP address blacklists – Removes downloads coming from IP addresses blacklisted for behavior not consistent with a website visitor or podcast listener (for example, a server caching content).
- Applying User Agent blacklists – Removes user agents that are known bots (computer programs that operate as an agent for a user or other program or to simulate a human activity).
- Ensures that at least one minute of playable content is downloaded.

UNIQUE: The Unique downloads algorithm accounts for two important pieces of information: IP Address and User Agent (Apple Podcasts, Chrome, etc.)

## Guidelines Pocketcards

*Provided by Guideline Central*

**Number of New Titles Completed:** 12 + 9 rapid updates

**Number of Hard Copies Distributed:** 3,452

**Number of Online Purchases:** 90

**Number of Online Viewers:** 28,671

**Number of New Paying Subscribers for ASCO titles: 49**

**Members Who Have Claimed Free Access:** Additional 688 claimed in 2023

ASCO 2023 Pocketcard Titles:

- Systemic Therapy for Small Cell Lung Cancer
- Systemic Therapy for Melanoma
- Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adult Patients with Cancer
- Cancer Cachexia
- Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy *Practical Assessment and Management*
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
- Anxiety and Depression in Adult Survivors of Cancer
- Penile Cancer
- Noncastrate Advanced, Recurrent or Metastatic Prostate Cancer
- Advanced Gastroesophageal Cancer *Immunotherapy and Targeted Therapy*

Rapid Updates:

- Management of Metastatic Clear Cell Renal Cell Carcinoma
- Stage IV Non-Small Cell Lung Cancer *With Driver Alterations Treatment*
- Stage IV Non-Small Cell Lung Cancer *Without Driver Alterations Systemic Therapy*
- Stage III Non-Small Cell Lung Cancer
- PARP Inhibitors in the Management of Ovarian Cancer
- HR-Positive, HER2-Negative Metastatic Breast Cancer Endocrine Treatment and Targeted Therapy
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Metastatic HER2-Negative Breast Cancer – Chemo-and Targeted Therapy *Either Endocrine-Pretreated or Hormone Receptor-Negative*
- HR-Positive, HER2-Negative Metastatic Breast Cancer *Endocrine Treatment and Targeted Therapy*

## Current Guidelines Landscape

### **Published and In Progress Guidelines (as of 2/1/24)**

Recently posted

- Germline Testing in Patients with Breast Cancer: ASCO-SSO Guideline Q and A
- Germline Testing in Patients with Breast Cancer: ASCO-SSO Guideline Systemic Treatment of Patients with Metastatic Breast Cancer: ASCO Resource-Stratified Guideline
- Systemic Treatment of Patients with Metastatic Breast Cancer: ASCO Resource-Stratified Guideline Q and A

Submitted/In press/ Submissions pending:

- Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations
- Cannabis and Cannabinoids in Adults with Cancer: ASCO Guideline Cannabis and Cannabinoids in Adults with Cancer: ASCO Guideline Summary and Q&A
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
- Prevention and Management of Osteoradionecrosis in Patients with Head and Neck Cancer Treated with Radiation Therapy: ISOO-MASCC-ASCO Guideline
- Vaccination of Adults with Cancer: ASCO Guideline
- Germline Genetic Testing: ASCO Guideline

#### Up for Review

- Management of Fatigue in Adult Survivors of Cancer: ASCO Guideline Update
- Palliative Care in Oncology: ASCO Guideline Update
- Management of Locally Advanced Rectal Cancer: ASCO Guideline
- Stage IV without driver alterations NSCLC living guidelines Update 2024.1
- Stage IV with driver alterations NSCLC living guidelines Update 2024.1
- Treatment of Pleural Mesothelioma: ASCO Guideline Update

#### All Published Guidelines (as of 2/1/24):

##### **Breast Cancer**

- Management of Hereditary Breast Cancer
- Management of Male Breast Cancer
- Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer
- Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
- Integrative Therapies During and After Breast Cancer Treatment
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- Estrogen and Progesterone Receptor Testing in Breast Cancer
- Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update
- Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Endorsement
- Chemo- and Targeted Therapy for Women with HER2 Negative (or unknown), Advanced Breast Cancer



- Use of Biomarkers to Guide Decisions on Systemic Therapy for Women with Metastatic Breast Cancer
- Breast Cancer Survivorship
- The Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Endorsement
- Endocrine Therapy for Hormone-Receptor Positive Advanced Breast Cancer
- Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ Endorsement
- Postmastectomy Radiotherapy
- Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer
- Adjuvant Bisphosphonates and other Bone-Modifying Agents in Non-metastatic Breast Cancer
- Use Of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer
- The Role of Bone Modifying Agents in Metastatic Breast Cancer
- HER2 Testing in Breast Cancer
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
- Systemic Therapy for Patients with Advanced HER2-positive Breast Cancer
- Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases
- Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer Update
- Use of Endocrine Therapy for Breast Cancer Risk Reduction
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
- Management of the Axilla in Early-Stage Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
- Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: Rapid Recommendation Update 1
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative Rapid Recommendation 2
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer Rapid Recommendation Update
- Testing for ESR1 Mutations to Guide Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update

## **Gastrointestinal Cancer**

- Systemic Therapy for Advanced Hepatocellular Carcinoma
- Treatment of Locally Advanced Esophageal Carcinoma
- Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline
- Early Detection for Colorectal Cancer Resource-Stratified Guideline
- Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline
- Adjuvant Chemotherapy for Stage II Colon Cancer
- Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer Endorsement
- Hereditary Colorectal Cancer Syndromes Endorsement
- Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-EGFR Monoclonal Antibody Therapy
- Locally Advanced Pancreatic Cancer
- Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology
- Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
- Metastatic Pancreatic Cancer Update
- Evaluating Susceptibility to Pancreatic Cancer
- Adjuvant Therapy for Resected Biliary Tract Cancer
- Duration of Oxaliplatin-containing Adjuvant Therapy for Stage III Colon Cancer
- Potentially Curable Pancreatic Adenocarcinoma
- Adjuvant Therapy for Stage II Colon Cancer
- Treatment of Metastatic Colorectal Cancer
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline
- Systemic Therapy for Tumor Control in Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

### **Genitourinary Cancer**

- Molecular Biomarkers in Localized Prostate Cancer
- Optimizing Anticancer Therapy in Metastatic Non-castrate Prostate Cancer
- Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer
- Uses of Serum Tumor Markers in Adult Males with Germ Cell Tumors
- Non-hormonal Therapy for Men with Metastatic Hormone-refractory (Castration-resistant) Prostate Cancer Endorsement
- Screening for Prostate Cancer with Prostate-Specific Antigen (PSA) Testing
- Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer
- Adjuvant and Salvage Radiotherapy After Prostatectomy Endorsement
- Prostate Cancer Survivorship Care Guideline Endorsement
- Active Surveillance for the Management of Localized Prostate Cancer

- Muscle-invasive and metastatic bladder cancer Endorsement
- Management of Small Renal Masses
- Brachytherapy for Patients with Prostate Cancer
- Second—Line Hormonal Therapy for Castration-Resistant Prostate Cancer PCO
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
- Optimizing anti-cancer therapy in non-castrate metastatic prostate cancer
- Clinically Localized Prostate Cancer
- Hypofractionated Radiation Therapy for Localized Prostate Cancer
- Molecular and Cellular Diagnostics in Localized Prostate Cancer
- Optimum Imaging Strategies for Advanced Prostate Cancer
- Bone Health and Bone-targeted Therapies for Prostate Cancer
- Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer
- Systemic Therapy in Men with Castration-Resistant Prostate Cancer Rapid Recommendation Update
- Management of Metastatic Clear Cell Renal Cell Carcinoma
- Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
- Penile Cancer: EAU-ASCO Collaborative Guidelines -2023 Update
- Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

### **Gynecologic Cancer**

- PARP Inhibitors in the Management of Ovarian Cancer
- Primary Prevention of Cervical Cancer Resource-Stratified Guideline
- Secondary Prevention of Cervical Cancer Resource-Stratified Guideline
- Neoadjuvant Chemotherapy for Ovarian Cancer
- Management and Care of Women with Invasive Cervical Cancer Resource-Stratified Guideline
- Postoperative Radiation Therapy for Endometrial Cancer Endorsement
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
- Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: Resource Stratified Guideline
- PARP Inhibitors in the Management of Ovarian Cancer: Rapid Recommendation Update

### **Head and Neck Cancer**

- Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage II to IVA Nasopharyngeal Carcinoma
- Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
- Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer

- Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
- Head and Neck Cancer Survivorship Care Endorsement
- Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma Endorsement
- Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
- Human Papillomavirus Testing in Head and Neck Carcinomas Endorsement
- Management of the neck in newly diagnosed squamous cell head and neck cancer
- De-escalation Protocols in the Management of p16+ Oropharyngeal Cancer
- Management of Salivary Gland Management
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers
- Hematologic Malignancies
- Role of Bone-Modifying Agents in Multiple Myeloma
- Initial Diagnostic Workup of Acute Leukemia Endorsement
- Treatment of Multiple Myeloma

### **Melanoma**

- Systemic Therapy for Melanoma
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma
- Systemic Therapy for Melanoma: Rapid Recommendation Update
- Systemic Therapy for Melanoma: ASCO Guideline Update

### **Molecular Testing and Biomarkers**

- Estrogen and Progesterone Receptor Testing in Breast Cancer
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
- Circulating Tumor DNA Analysis in Patients with Cancer: An ASCO/CAP Joint Review
- Molecular Testing for the Selection of Patients with Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline Endorsement
- Somatic and Genomic Testing in Patients with Metastatic or Advanced Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer

### **Neuro-Oncology**

- Recommendations on Disease Management for Patients with Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- Radiation Therapy for Glioblastoma Endorsement
- Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors
- Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults
- Treatment for Brain Metastases
- Radiation Therapy for Brain Metastases Endorsement

### **Patient and Survivor Care**

- Palliative Care in the Global Setting Resource-Stratified Guideline
- Chronic Pain in Cancer Survivors
- Patient-Clinician Communication
- Interventions to Address Sexual Problems in People with Cancer Adaptation
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers
- Fertility Preservation Patients with Cancer
- Screening, Assessment and Management of Fatigue in Adult Survivors of Cancer Adaptation
- Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults with Cancer Adaptation
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers
- Management of Osteoporosis in Survivors of Adult Cancers with Non-Metastatic Disease
- Integrative Medicine for Pain Management in Oncology
- Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update
- Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults with Cancer: SIO-ASCO Guideline
- Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments

#### **Resource-Stratified**

- Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline
- Early Detection for Colorectal Cancer Resource-Stratified Guideline
- Treatment of Patients with Early-Stage Colorectal Cancer Resource-Stratified Guideline
- Management and Care of Women with Invasive Cervical Cancer
- Cervical Cancer Secondary Prevention/early disease
- Cervical Cancer Primary Prevention
- Palliative Care in the Global Setting
- Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: Resource-Stratified Guideline

#### **Supportive Care and Treatment-Related Issues**

- Metastatic Carcinoma and Myeloma of the Femur
- Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
- Management of Cancer Cachexia
- Use of Chemotherapy and Radiation Therapy Protectants
- Appropriate Chemotherapy Dosing for Obese Adult Patients with Cancer
- Guideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem Cell Transplantation Endorsement
- Central Venous Catheter Care for the Oncology Patient
- Hepatitis B Virus Screening for Patients with Cancer Prior to Therapy
- Use of White Blood Cell Growth Factors:

- Antiemetics
- The Integration of Palliative Care into Standard Oncology Care
- Platelet Transfusion for Patients with Cancer
- Patient-Clinician Communication
- Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy
- Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
- Use of Integrative Therapies During and After Breast Cancer Treatment Guideline Endorsement
- Antimicrobial Prophylaxis in Immunocompromised Patients
- Management of Cancer-associated Anemia with Erythropoiesis-Stimulating Agents (ASCO/ASH)
- Medication-Related Osteonecrosis of the Jaw
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
- Management of Dyspnea in Advanced Cancer
- Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
- Salivary Gland Hypofunction and/or Xerostomia Induced by Non-Surgical Cancer Therapies
- Management of Immune-Related Adverse Events in Patients Treatment with Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Exercise, Diet, and Weight Management During Cancer Treatment
- Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Guideline Update
- Cancer Cachexia: ASCO Guideline Rapid Recommendation
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update

### **Thoracic Cancer**

- The role of CT screening for lung cancer in clinical practice
- Epidermal Growth Factor Receptor (EGFR) Mutation Testing for People with Advanced Non-Small Cell Lung Cancer Considering an EGFR Tyrosine-Kinase (TKI) Inhibitor
- Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Endorsement
- Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations
- Treatment of Small Cell Lung Cancer: Endorsement
- Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer Endorsement
- Treatment of Malignant Pleural Mesothelioma
- Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Endorsement
- Lung Cancer Surveillance After Definitive Curative-Intent Therapy
- Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A Resectable Non-Small Cell Lung Cancer

- Radiation Therapy for Small Cell Lung Cancer
- Management of Stage III NSCLC
- Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
- Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
- Systemic Therapy for SCLC: ASCO-Ontario Health (Cancer Care Ontario) Guideline

### **Spanish Language Translations**

- Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer
- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer
- Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
- Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer
- Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
- Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative
- Management of Metastatic Clear Cell Renal Cell Carcinoma
- Management and Care of Women with Invasive Cervical Cancer Resource-Stratified Guideline
- Systemic Therapy for Melanoma
- Radiation Therapy for Brain Metastases Guideline Endorsement
- Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy
- Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
- Exercise, Diet, and Weight Management During Cancer Treatment
- Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A Resectable Non-Small Cell Lung Cancer
- Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations
- Therapy for Stage IV Non-Small Cell Lung Cancer without Driver Alterations

### **Standards**

- Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology
- Safe Handling of Hazardous Drugs: ASCO Standards
- Patient-Centered Standards for Medically Integrated Dispensing
- Oncology Medical Home: ASCO and COA Standards
- Telehealth in Oncology: ASCO Standards and Practice Recommendations

### **Guideline Priorities 2023-2024**

## **Breast Cancer**

- Disease Management for Patients with Advanced HER2–positive Breast Cancer and Brain Metastases (Update)
- Use of Endocrine Therapy for Breast Cancer Risk Reduction (Update)
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer (Update)
- Transgender Breast Cancer Care (New)

## **Gastrointestinal Cancer**

- De Novo: Systemic Therapy for Advanced Biliary Tract Cancer (New)
- Immunotherapy and Targeted Therapy for Advanced Gastro/Esophageal Carcinoma (Update)
- Locally Advanced Esophageal (Update)
- De Novo: Local and Regional Therapies, Including Adjuvant Therapy, for Locally Advanced HCC (New)
- De Novo: Local and Regional Therapies for Biliary Tract Cancer (New)

## **Genitourinary Cancer**

- Post-operative radiotherapy After Prostatectomy (Update)
- Primary Tumor-Directed and Metastasis-Directed Local Therapy in metastatic Prostate Cancer (New)
- Special Considerations for Older Patients with Genitourinary Cancers (New)
- Genitourinary Cancers Survivorship (New)
- Adjuvant treatment of localized and oligometastatic RCC after definitive therapy (New)

## **Gynecologic Cancer**

- First Platinum-Sensitive ovarian cancer recurrence (New)
- Gynecologic Cancers Survivorship (New)
- Treatment of Invasive Cervical Cancer (New)
- Recurrent Endometrial Cancer (New)

## **Head and Neck Cancer**

- Use of systemic treatment in the management of advanced thyroid cancer (New)
- Management of advanced cutaneous squamous cell of the H&N (New)
- Management of head and neck cancers in the older adults (80+) and/or frail patient population (New)
- Management of locoregionally recurrent head and neck cancer (New)
- Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer (Update)

## **Hematological Malignancies**

- Management of Side Effects from Immune Effector Cell Therapy (New)



- Update of Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor (CAR) T-Cell Therapy AND Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy
- Treatment of Relapsed/Refractory Aggressive Lymphomas (New)
- Risk-based Management of MDS (New)

#### **Multi-Site**

- Systemic Therapy for Sarcoma (New)
- Treatment of Leptomeningeal Metastases (New)
- Treatment of Non-Melanoma Skin Cancer (New)

#### **Resource Stratified**

- Geriatric Oncology (New)
- Survivorship Care in Adolescents, Young Adults, and Adults (New)
- Treatment of Patients with Endometrial Cancer (New)

#### **Supportive Care**

- Integration/Implementation of Patient-reported outcomes in cancer care (New)
- Cancer and treatment related cognitive impairment (New)
- Addressing the needs of informal caregivers of people living with cancer (New)

#### **Patient & Survivor Care**

- Young Adult Survivorship guideline for ages 21-39 (New)
- Management of sleep problems in cancer survivors (New, in collaboration with Society of Integrative Oncology)
- Survivorship after Stem Cell Transplant (New)
- Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers (Update)

#### **Thoracic Cancer**

- Management of Stage I Non-Small Cell Lung Cancer (New)
- Molecular Testing for the Selection of Patients with Lung Cancer for Treatment with Targeted Tyrosine Kinase Inhibitors Guideline Endorsement (Update)
- Management of Multifocal Lung Adenocarcinoma (New)
- Duration of Systemic Therapy for Stage IV Lung Cancer (New)

## Collaborating Organizations

- American Cancer Society
- American College of Cardiology
- American College of Chest Physicians
- American College of Radiology
- American Heart Association
- American Society for Clinical Pathology
- American Society for Radiation Oncology
- American Society of Echocardiography
- American Society of Hematology
- American Urological Association
- Association for Molecular Pathology
- Cancer Care Ontario
- Centers for Disease Control and Prevention
- College of American Pathologists
- Congress of Neurological Surgeons
- European Association of Urology
- European Society of Medical Oncology
- Hematology/Oncology Pharmacy Association
- Infectious Diseases Society of America
- International Association for the Study of Lung Cancer
- International Society of Oral Oncology
- Multinational Association of Supportive Care in Cancer
- Musculoskeletal Tumor Society
- National Cancer Institute Physician Data Query
- National Comprehensive Cancer Network
- Oncology Nursing Society
- Pediatric Oncology Group of Ontario
- Society for Immunotherapy of Cancer
- Society for Integrative Oncology
- Society for Neuro-Oncology
- Society of Abdominal Radiology
- Society of Gynecologic Oncology
- Society of Surgical Oncology
- Society of Urologic Oncology
- Society of Nuclear Medicine and Molecular Imaging
- U.S. Food and Drug Administration

**Breast Cancer**

Disease Site	Screening and Diagnosis			Treatment							Ongoing Care							
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery			Radiotherapy	Chemotherapy	Hormonal and Other Therapies		Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship				
DCIS	1.05		1.02 1.03 1.06 1.30	1.24	1.20 1.27	1.02	1.24	1.01 1.27	1.23 1.27 1.31	1.07 1.21 1.17	1.14 1.18 12.09	1.08 1.09 1.31 1.14	1.22	1.10	8.07 9.08 12.04	8.19	9.13	
BRCA1/BRCA2 Mutation		1.32		1.29			1.29											1.29
Hormone receptor-positive																		
HER2-positive				1.04 1.15			1.21											
HER2-negative																		
Triple-negative																		
Male Breast Cancer			1.30															

Blue Text: Current  
 Gray Italics: Archived  
 Green Text: Being Updated  
 Red Text: New Guideline in Development  
 Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
1.01	Breast	Postmastectomy Radiotherapy	Guideline Update	ASCO-ASTRO-SSO	Current	Abram Recht, Stephen Edge	9/3/2019
1.02	Breast	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer	Guideline Update	n/a	Current	Armando Giuliano, Gary Lyman	1/13/2020
1.03	Breast	HER2 Testing in Breast Cancer	Guideline Update	ASCO-CAP	In Progress	Antonio Wolff, Liz Hammond	6/25/2018
1.05	Breast	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction	Guideline Update	n/a	Current	Kala Visvanathan, Carol Fabian	9/6/2011
1.06	Breast	Estrogen and Progesterone Receptor Testing in Breast Cancer	Guideline Update	ASCO-CAP	Current	Kim Allison, Antonio Wolff	3/1/2012
1.07	Breast	Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer	Guideline Update	n/a	Current	Nancy Davidson, Sharon Giordano	7/29/2021
1.08	Breast	Role of Bone-Modifying Agents in Metastatic Breast Cancer	Guideline Update	ASCO-CCO	Current	Beverly Moy, Catherine Van Poznak	5/31/2019
1.09	Breast	Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer	Endorsement	CCO Endorsement	Archived		7/29/2021
1.10	Breast	Breast Cancer Follow-Up and Management After Primary Treatment	Guideline Update	n/a	Current	James Khatcheressian, Nancy Davidson	7/29/2021
1.14	Breast	Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer Update	Guideline Update	n/a	In Progress	Harold Burstein, Jennifer Griggs	5/7/2014
1.15	Breast	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer	Guideline Update	n/a	Current	Fabrice Andre, Vered Stearns	6/25/2018
1.17	Breast	Chemotherapy for HER2 Negative Advanced Breast Cancer	De Novo Guideline	n/a	Current	Beverly Moy, Lisa Carey	6/17/2019
1.18	Breast	Endocrine therapy for hormone receptor positive metastatic breast cancer	De Novo Guideline	n/a	Current	Harold Burstein	10/20/2020
1.20	Breast	Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer	Endorsement	SSO-ASTRO	Current	Thomas A. Buchholz, Lisa A. Newman	8/15/2016
1.21	Breast	Disease Management for Patients With Advanced HER2-Positive Breast Cancer and Brain Metastases	De Novo Guideline	n/a	Current	Naren Ramakrishna, Nancy Lin	3/6/2017
1.22	Breast	Endorsement of the Cancer Care Ontario patient/disease characteristics and recurrence risk recommendations	Endorsement	CCO Endorsement	Current	N. Lynn Henry, Vered Stearns	
1.23	Breast	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline	Guideline Update	CCO Adaptation	Current	Neelima Denduluri, Sharon Giordano	7/19/2021
1.24	Breast	Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Ductal Carcinoma In Situ	De Novo Guideline	SSO-ASTRO-ASCO	Current	Monica Morrow	
1.25	Breast	Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer	De Novo Guideline	CCO-ASCO	Current	Catherine Van Poznak, Andea Eisen	8/3/2021
1.26	Breast	Whole Breast Irradiation	Endorsement	ASTRO Endorsement	Current	Armando Giuliano, Abram Recht	2/14/2020
1.27	Breast	Management of the Axilla	De Novo Guideline	CCO-ASCO	Project Terminated	Muriel Brackstone	1/28/2021
1.28	Breast	Autologous Breast Reconstruction	Endorsement	ASPS Endorsement	Current	Colleen McCarthy, Kelly Hunt	
1.29	Breast	Hereditary Breast Cancer	De Novo Guideline	ASCO-ASTRO-SSO	Project Terminated	Nadine Tung, Dana Zakalik	4/3/2020
1.30	Breast	Management Male Breast Cancer	De Novo Guideline	n/a	Current	Sharon Giordano, Mike Hassett	2/14/2020
1.31	Breast	Neoadjuvant therapy in locally advanced breast cancer	De Novo Guideline	n/a	Current	Dawn Hershman, Larissa Korde	1/28/2021
1.32	Breast	Germline Testing in Patients with Breast Cancer	De Novo Guideline	ASCO-SSO	Current	Mark Robson, Isabelle Bedrosian	1/4/2024
8.19	Supportive Care	Integrative Therapies During and After Breast Cancer Treatment	Endorsement	SIO Endorsement	Current	Gary Lyman, Lorenzo Cohen	6/11/2018
9.13	Survivorship	Breast Cancer Survivorship Care Guideline	De Novo Guideline	ACS-ASCO			12/7/2015
12.09	Resource-Stratified	Treatment of Patients with Metastatic Breast Cancer Resource-Stratified Guideline	De Novo Guideline		Current	Sana Al Sukhun, Banu K. Arun	1/10/2024

**Gastrointestinal Cancer**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Biliary				2.24 P.01	2.24 P.01	2.18 2.24 P.01	2.22 2.23 2.24 P.01				
Colorectal	2.09	2.09 12.05	2.04 2.06	2.09 12.06 12.07 2.20 P.03 P.04	12.06 12.07 2.20 P.03 P.04	2.01 12.06 12.07 2.19 2.20 P.03 P.04	2.20 P.03 P.04	2.02 2.09 12.06 12.07			
Esophageal			2.08 2.14	2.08 2.14	2.08 2.14	2.08 2.14 2.21	2.21	2.08			
Liver						2.17					
Neuroendocrine											
Pancreatic		2.16		2.12	2.11 2.12 2.13	2.11 2.12 2.13					
Stomach		P.02	2.14 P.02	2.14 P.02	2.14	2.14					

Blue Text: Current  
 Gray Italics: Archived  
 Green Text: Being Updated  
 Red Text: New Guideline in Development  
 Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
2.01	Gastrointestinal	Adjuvant therapy for stage II colon cancer	Guideline Update		Current	Nancy Baxter, Jeffrey Meyerhardt	12/22/2021
2.02	Gastrointestinal	Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures f	Endorsement	CCO Endorsement	Current	Al B. Benson, Jeffrey A. Meyerhardt	11/12/2013
2.04	Gastrointestinal	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to I	PCO	n/a	Archived	Carmen J. Allegra, Richard L. Schilsky	10/5/2015
2.06	Gastrointestinal	Molecular Markers for the Evaluation of Colorectal Cancer	De Novo Guideline	ASCP-CAP-AMP-AS	Current	Antonia Sepulveda (AMP), Wayne W. Grody (ASCP), S	2/6/2017
2.08	Gastrointestinal	Treatment of Locally Advanced Esophageal Carcinoma	De Novo Guideline	n/a	Current	Manish Shah, Wayne Hofstetter	8/18/2021
2.09	Gastrointestinal	Hereditary Colorectal Cancer Syndromes: ASCO Endorsement of the Familial	Endorsement	ESMO Endorsemen	Current	Paul Limburg, Elena Stoffel	12/1/2014
2.11	Gastrointestinal	Metastatic Pancreatic Cancer	Guideline Update	n/a	Current	Dan Laheru, Davendra Sohal	8/5/2020
2.12	Gastrointestinal	Resectable Pancreatic Cancer	Guideline Update	n/a	Current	Alok Khorana, Matt Katz	6/10/2019
2.13	Gastrointestinal	Locally Advanced Pancreatic Cancer	De Novo Guideline	n/a	Current	Ed Balaban, Nelson Yee	5/31/2016
2.14	Gastrointestinal	HER2 Testing in Gastric Cancer	De Novo Guideline	ASCO-CAP	Current	Angela Barley (CAP), Mary Kay Washington (ASCP), Ja	11/14/2016
2.16	Gastrointestinal	Pancreatic Hereditary PCO	PCO	n/a	Current	Elena Stoffel, Alok Khorana	11/20/2018
2.17	Gastrointestinal	Systemic Therapy for Advanced Hepatocellular Carcinoma	De Novo Guideline	n/a	Current	John Gordan, Michal Rose	11/16/2020
2.18	Gastrointestinal	Adjuvant Therapy for Biliary Tract Cancer	De Novo Guideline	n/a	Current	Rachna Shroff, Shishir Maithel	3/11/2019
2.19	Gastrointestinal	Adjuvant therapy for stage III colon cancer	De Novo Guideline	n/a	Current	Nancy Baxter, Christopher Lieu	4/15/2019
2.20	Gastrointestinal	Treatment options for Advanced Colon Cancer	De Novo Guideline	n/a	Current	Cathy Eng, Van Morris	12/22/2021
2.21	Gastrointestinal	Targeted Therapy for Gastroesophageal Cancer	De Novo Guideline	n/a	Current	Manish Shah, Lakshmi Rajdev	1/5/2023
2.23	Gastrointestinal	Systemic Therapy for Neuroendocrine Tumors	De Novo Guideline	n/a	Current		9/29/2023
2.24	Gastrointestinal	Neoadjuvant and Adjuvant Therapy for Rectal Cancer (including nonoperative	De Novo Guideline	n/a	In Progress		
2.26	Gastrointestinal	Treatment Options for Anal Cancer	De Novo Guideline	n/a	In Progress	Cathy Eng, Van Morris	
12.05	Resource-Stratified	RSG CRC early detection	De Novo Guideline	n/a	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto	2/25/2019
12.06	Resource-Stratified	RSG CRC tx early stage	De Novo Guideline	n/a	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto	2/25/2019
12.07	Resource-Stratified	RSG CRC tx late stage	De Novo Guideline	n/a	Current	Gabriela Chiorean, Mary Chamberlin	
P.01	Gastrointestinal	Systemic Therapy (including Targeted Therapy) for Biliary Tract Cancer					
P.02	Gastrointestinal	Immunotherapy and Targeted Therapy for Advanced Gastro/Esophageal Carcinoma					
P.03	Gastrointestinal	Local and Regional Therapies, Including Adjuvant Therapy, for Locally Advanced HCC					
P.04	Gastrointestinal	Local and Regional Therapies for Biliary Tract Cancer					

**Genitourinary Cancer**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Bladder				3.11 3.14	3.11 3.14	3.11 3.14	3.11 3.14				P.06
Kidney				3.08	3.08 3.22 P.08	3.22 P.08	3.08 3.22 P.08				P.06
Penile									8.07 9.08 12.04	3.21 P.07	P.06
Prostate	3.19	3.04 3.24	3.15 3.16 3.18	3.18 P.05	3.09 3.13 3.17 3.18 P.05	3.02 3.05	3.01 3.06 3.18 3.20	3.10 3.12 3.18			9.09 P.06
Germ Cell Tumors			3.03								P.06

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
3.01	Genitourinary	Initial Hormonal Management of Androgen-Sensitive M	Guideline Update	n/a	Current	Kathy Virgo, James Talcott	1/26/2021
3.02	Genitourinary	Non-Hormonal Therapy for Men With Metastatic Horm	Endorsement	CCO Endorsement	Archived		11/20/2007
3.03	Genitourinary	Uses of Serum Tumor Markers in Adult Males with Gerr	De Novo Guideline	n/a	Current	Tim Gilligan, Dan Hayes	7/10/2010
3.04	Genitourinary	Screening for Prostate Cancer with Prostate-Specific An	PCO	n/a	Archived	Karen Hoffman, Robert Nam	2/16/2012
3.05	Genitourinary	Systemic Therapy for Metastatic Castration Resistant Pr	Guideline Update	n/a	Current	Ethan Basch	9/8/2014
3.06	Genitourinary	2nd Line Hormonal Therapy for Castration Resistant Pr	PCO	n/a	Current	Katherine Virgo, Eric Singer	4/25/2017
3.08	Genitourinary	Management of small renal masses	De Novo Guideline	n/a	Current	Tony Finelli, Paul Russo	1/17/2017
3.09	Genitourinary	AUA/ASTRO CPG on adjuvant RT following radical prost	Endorsement	AUA-ASTRO Endorse	Current	Howard Sandler, Stephen Freedland	11/3/2014
3.10	Genitourinary	Androgen deprivation therapy with or without chemoth	De Novo Guideline	n/a	Current	Matthew Milowsky, Cheryl Lee	3/21/2016
3.11	Genitourinary	Guidelines on muscle-invasive and metastatic bladder c	Endorsement	EAU Endorsement	Current	Ronald Chen, Suniel Jain	2/16/2016
3.12	Genitourinary	Active Surveillance Endorsement	Endorsement	CCO Endorsement	Current	Andrew Loblaw, Joseph Chin	3/27/2017
3.13	Genitourinary	Brachytherapy in Prostate Cancer	Guideline Update	ASCO-CCO	Current		8/10/2017
3.14	Genitourinary	ASCO-AUA Bladder Cancer Guideline	De Novo Guideline	AUA-ASCO-ASTRO-SU	Current	Scott E. Eggener, AUA rep, Co-Chair, t	12/12/2019
3.15	Genitourinary	Guidelines for the use of molecular and cellular diagnos	De Novo Guideline	ASCO-EAU-AUA-CAP	Current	Alberto Vargas, Edouard Trabulsi Scott Morgan,	1/15/2020
3.16	Genitourinary	Optimum imaging strategies for advanced prostate can	De Novo Guideline	ASCO-SAR-ACR-SNM	Current	Howard Sandler	10/11/2018
3.17	Genitourinary	Hypofractionated RT for localized prostate cancer	De Novo Guideline	ASTRO-ASCO-AUA	Current	Karim Touijer, Andrew Stephenson, J	9/5/2018
3.18	Genitourinary	ASCO Endorsement of the AUA Localized prostate canc	Endorsement	AUA Endorsement	Under Review for	Update	3/20/2009
3.19	Genitourinary	Use of 5-alpha Reductase Inhibitors for Prostate Cancer	Guideline Update	ASCO-AUA	Current	Philip Saylor, Jeff Michalski	1/28/2020
3.20	Genitourinary	Bone Health and Bone-targeted Therapies for Prostate	De Novo Guideline	n/a	Current		1/28/2020
3.21	Genitourinary	Special considerations for elderly patients with genitou	De Novo Guideline	n/a	In Progress		
3.22	Genitourinary	Management of metastatic renal clear cell cancer	De Novo Guideline	n/a	Current	Eric Singer, Kimryn Rathmell	9/11/2023
3.23	Genitourinary	Node Positive Prostate Cancer	De Novo Guideline	n/a	In Progress		
3.24	Genitourinary	Germline and Genomic Testing in Advanced Prostate Ca	De Novo Guideline	n/a	In Progress		
3.25	Genitourinary	Penile Cancer	De Novo Guideline	ASCO-EAU	Current		3/10/2023
P.05	Genitourinary	Primary Tumor-Directed and Metastasis-Directed Local	Therapy in metastatic Prostate Cancer				
P.06	Genitourinary	Post-operative radiotherapy After Prostatectomy					
P.07	Genitourinary	Special Considerations for Elderly Patients with Genitourinary Cancers					
P.08	Genitourinary	Adjuvant Treatment of Localized and Oligometastatic RCC After Definitive Therapy					

**Gynecologic Cancer**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Cervical	12.01	12.02		12.03 P.11	12.03 P.09 P.11	12.03 P.11	12.03 P.11				P.10
Endometrial/ Uterine				P.12	11.01 P.12						P.10
Ovarian			11.03	12.08	12.08	11.02 12.08 P.09	11.04 12.08				P.10
Vaginal											P.10
Vulvar											P.10

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
11.01	Gynecologic	Postoperative Radiation Therapy for Endometrial Cancer	Endorsement	ASTRO Endorsement	Current	Larissa Meyer, Alexi Wright	7/6/2015
11.02	Gynecologic	NACT for Newly Diagnosed, Advanced Ovarian Cancer	De Novo Guideline	ASCO-SGO	Current	Alexi Wright, Mitchell Edelson	8/8/2016
11.03	Gynecologic	Germline and somatic tumor testing	De Novo Guideline	n/a	Current	Christina Annunziata, Panos Konstantinopoulos	1/27/2020
11.04	Gynecologic	PARP Inhibitors in the Management of Ovarian Cancer	De Novo Guideline	n/a	Current	Bill Tew, Elise Kohn	8/13/2020
11.05	Gynecologic	Adjuvant therapy for high risk endometrial cancer	De Novo Guideline	n/a	In Progress		
11.06	Gynecologic	Recurrent Endometrial Cancer	De Novo Guideline	n/a	In Progress		
12.01	Resource-Stratified	Cervical Cancer Primary Prevention	De Novo Guideline	n/a	Current	Silvina Arrossi, Silvia de Sanjose	3/17/2017
12.02	Resource-Stratified	Cervical Cancer Secondary Prevention	De Novo Guideline	n/a	Current	Jose Jeronimo, Surenda Srinivas Shastri	10/12/2016
12.03	Resource-Stratified	Cervical Cancer Workup and Treatment	De Novo Guideline	n/a	Current	Jonathan Berek, Linus Chuang	5/25/2016
12.08	Resource-Stratified	RSG Ovarian Cancer	De Novo Guideline	n/a	Current	Jean Rene Clemenceau, Verna Vanderpuye	6/29/2021
P.09	Gynecologic	First Platinum-Sensitive ovarian cancer recurrence					
P.10	Gynecologic	Gynecologic Cancers Survivorship					
P.11	Gynecologic	Treatment of Invasive Cervical Cancer					

### Head and Neck Cancer

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Cross-cutting/ undefined scope				P.14 P.15 P.16	P.14 P.15 P.16	P.14 P.15 P.16	P.14 P.15 P.16		P.16		
Laryngeal and hypopharyngeal				4.01	4.01	4.01	4.01				9.14
Nasal cavity and paranasal sinus											
Nasopharyngeal							4.09				
Oral and oropharyngeal			4.04	4.03 4.06 4.11	4.02 4.03 4.06	4.03 4.06					
Salivary gland				4.07	4.07	4.07					
Thyroid					P.13						
Unknown Primary			4.04 4.05	4.05	4.05	4.05					

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
4.01	Head & Neck	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer	De Novo Guideline	n/a	Current	Arlene Forastiere, Greg Wolf	11/27/2017
4.02	Head & Neck	ASTRO Oropharyngeal Guideline Endorsement	Endorsement	ASTRO Endorsement	Current	Harry Quon, Arlene Forastiere, Neha	10/24/2017
4.03	Head & Neck	Management of the neck in newly diagnosed squamous cell head and neck cancer	De Novo Guideline	n/a	Current	Chris Holsinger, Shlomo Koyfman	2/27/2019
4.04	Head & Neck	HPV Testing in Head and Neck Squamous Cell Carcinoma	Endorsement	CAP Endorsement	Current	Bayardo Perez-Ordonez, Carole Fakih	9/6/2018
4.05	Head & Neck	Diagnosis and Management of Cancer of Unknown Primary in the Head and Neck	De Novo Guideline	n/a	Current	Ellie Maghami, Jimmy Caudell	4/23/2020
4.06	Head & Neck	Role of De-Escalation Protocols in the Management of p16+ Oropharyngeal Cancer	PCO	n/a	Current	David Adelstein, Drew Ridge	4/25/2019
4.07	Head & Neck	Management of salivary gland malignancy	De Novo Guideline	n/a	Current	Jessica Geiger, Patrick Ha	4/26/2021
4.08	Head & Neck	Treatment of Nasopharyngeal Cancer			Current	Jun Ma, Ying Sun	
4.09	Head & Neck	Use of immune checkpoint inhibitors and PD-L1 testing in HNSCC focusing on recurrent/metastatic disease			In Progress		
4.10	Head & Neck	ORN			In Progress		
4.11	Head & Neck	Transoral Robotic Surgery for Oropharynx Cancer			In Progress		
9.14	Survivorship	Head and Neck Cancer Survivorship Care Guideline	Endorsement	ACS Endorsement	Current	Larissa Nekhlyudov, Lillian Siu	2/27/2017
P.13	Head & Neck	Use of Systemic Treatment in the Management of Advanced Thyroid Cancer					
P.14	Head & Neck	Management of Advanced Cutaneous Squamous Cell of the Head and Neck					
P.15	Head & Neck	Management of Locoregionally Recurrent Head and Neck Cancer					
P.16	Head & Neck	Management of Head and Neck Cancers in the Very Elderly (80+) and/or Frail Patient Population					

### Hematologic Malignancies

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Leukemia			5.02	P.17	P.17	P.17	P.17				
Non-Hodgkin lymphoma				P.18	P.18 P.19	P.18 P.19	P.18 P.19				
Hodgkin lymphoma											
Multiple myeloma						5.03	5.01	5.03			

Blue Text: Current

*Gray Italics: Archived*

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
5.01	<b>Hematologic Mali</b>	Bone Modifying Agents in Multiple Myeloma Update	Guideline Update	n/a	Current	Kenneth Anderson, Robert A. Kyle	1/17/2018
5.02	<b>Hematologic Mali</b>	CAP/ASH Acute Leukemia Endorsement	Endorsement	CAP-ASH Endorsement	Current	Valerie De Haas, Ling Zhang	12/3/2018
5.04	<b>Hematologic Mali</b>	Management of Patients with Multiple Myeloma	De Novo Guideline	n/a	Current	Joe Mikhael, Tom Martin	4/1/2019
5.03	<b>Hematologic Mali</b>	Therapy of Newly Diagnosed CLL Guideline	De Novo Guideline		In Progress		
P.17	<b>Hematologic Mali</b>	Management of Side Effects from Immune Effector Cell Therapy					
P.18	<b>Hematologic Mali</b>	Treatment of Relapsed/Refractory Aggressive Lymphomas					
P.19	<b>Hematologic Mali</b>	New Risk-Based Management of Myelodysplastic Syndromes					



**Neurooncology**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Femur				13.08	13.08						
Glioma					13.02	13.07					
Metastatic Brain Tumors					13.04 13.10	13.04	13.05			13.05	

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
13.02	Neurooncology	Radiation Therapy for Glioblastoma	Endorsement	ASTRO Endorsement	Current	Susan Chang, Eric Sulman	11/28/2016
13.04	Neurooncology	Treatment of Brain Metastases	De Novo Guideline	Society of Neuro-Oncology	Current	Michael Vogelbaum, David Schiff	12/21/2021
13.05	Neurooncology	Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors	Endorsement	Society of Neuro-Oncology	Current	Susan Chang, Michael Vogelbaum	3/18/2019
13.07	Neurooncology	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors	De Novo Guideline	n/a	Current	Nimish Mohile, Jaishri Blakeley	12/13/2021
13.08	Neurooncology	Treatment of Metastatic Carcinoma and Myeloma of the Femur	De Novo Guideline	MSTS-AAOS-ASCO	Current	David Schiff, Michael Vogelbaum	
13.10	Neurooncology	Radiation for Brain Metastases (ASTRO Endorsement)	Endorsement	ASTRO Endorsement	Current		

**Resource-Stratified**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Breast				12.09	12.09	12.09	12.09		12.04		P.20
GI		12.05		12.06 12.07	12.06 12.07	12.06 12.07		12.06 12.07			
GU											
Geriatric Onc									12.04		P.20
Gyn	12.01	12.02		12.03 12.08 P.21 P.22	12.03 12.08 P.21 P.22	12.03 12.08 P.21 P.22	12.03 12.08 P.21 P.22		12.04 P.21		P.20
H&N											
Hem											
Neuro-onc											
Ophthalmic											
Pediatric											
Sarcoma											
Skin											
Thoracic											

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Status	Co-Chairs	Date of Last
12.01	Resource-Stratified	Cervical Cancer Primary Prevention	De Novo Guidelin	Current	Silvina Arrossi, Silvia de Sanjose	3/17/2017
12.02	Resource-Stratified	Cervical Cancer Secondary Prevention	De Novo Guidelin	Current	Jose Jeronimo, Surenda Srinivas Shastri	10/12/2016
12.03	Resource-Stratified	Cervical Cancer Workup and Treatment	De Novo Guidelin	Current	Jonathan Berek, Linus Chuang	5/25/2016
12.04	Resource-Stratified	Global Palliative Care	De Novo Guidelin	Current	Jim Cleary, Hibah Osman	5/8/2018
12.05	Resource-Stratified	RSG CRC early detection	De Novo Guidelin	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto Lopes, Manish Sha	2/25/2019
12.06	Resource-Stratified	RSG CRC tx early stage	De Novo Guidelin	Current	Ainhua Costas-Chavarri, Marcia Cruz Correa, Gilberto Lopes, Manish Sha	2/25/2019
12.07	Resource-Stratified	RSG CRC tx late stage	De Novo Guidelin	Current	Gabriela Chiorean, Mary Chamberlin	3/9/2020
12.08	Resource-Stratified	RSG Ovarian Cancer	De Novo Guidelin	Current	Jean Rene Clemenceau, Verna Vanderpuye	6/29/2021
12.09	Resource-Stratified	RSG MBC adaptation	De Novo Guidelin	Current	Sana Al Sukhun, Banu K. Arun	1/10/2024
P.20	Resource-Stratified	Survivorship Care in Adolescents, Young Adults, and Adults				
P.21	Resource-Stratified	Geriatric Oncology				
P.22	Resource-Stratified	Treatment of Patients with Endometrial Cancer				

Supportive Care					
Disease-Specific		Mix of Cancer Types	Geriatric Oncology	Pediatric Oncology	Resource Stratified
Breast	8.19	8.01			
GI		8.02			
		8.03			
GU		8.04			
		8.05			
Gyn		8.06			
		8.07			
		8.08			
H&N		8.09			
		8.101			
		8.102			
Hem		8.11		8.01	
		8.12		8.02	
		8.14	13.01	8.06	12.04
		8.16		8.09	
Neuro-onc	13.05	8.17		8.11	
		8.18			
		8.20			
Ophthalmic		8.22			
		8.23			
Sarcoma		8.24			
		8.25			
Skin	P.24	8.26			
		8.27			
		9.08			
Thoracic	P.25	12.04			
		P.23			

Blue Text: Current  
 Gray Italics: Archived  
 Green Text: Being Updated  
 Red Text: New Guideline in Development  
 Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
8.01	Supportive Care	Platelet Transfusion for Patients With Cancer	Guideline Update	n/a	Current	Charles Schiffer, Ken Anderson	11/28/2017
8.02	Supportive Care	White Blood Cell Growth Factors	Guideline Update	n/a	Current	Thomas J. Smith, Jim Armitage	7/13/2015
8.03	Supportive Care	Use of Chemotherapy and Radiation Therapy Protectants Update	Guideline Update	n/a	Archived	Martee L. Hensley, Lynn M Schuchter	1/1/2009
8.04	Supportive Care	Hepatitis B Virus Screening and Management for Patients with PCO	Guideline Update	n/a	Current	Andrew S. Artz, Jessica P. Hwang	7/27/2020
8.05	Supportive Care	Management of Cancer-associated Anemia with ESAs	Guideline Update	ASCO-ASH	Current	Julia Bohlius, Alejandro Lazo-Langer	4/10/2019
8.06	Supportive Care	Antiemetics Update	Guideline Update	n/a	Current	Paul J. Hesketh, Mark G. Kris	7/13/2020
8.07	Supportive Care	The Integration of Palliative Care into Standard Oncology Care	Guideline Update	n/a	Under Review for Endorsement	Thomas J. Smith, Betty R. Ferrell	10/31/2016
8.08	Supportive Care	Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer	Guideline Update	n/a	Current	Jennifer Griggs, Gary Lyman	5/3/2021
8.09	Supportive Care	Guideline for the Management of Fever and Neutropenia in Children	Guideline Update	n/a	Current	Jennifer Griggs, Gary Lyman	1/14/2013
8.101	Supportive Care	Outpatient Management of Fever and Neutropenia in Adult Patients	Guideline Update	ASCO-IDS	Current	Christopher R. Flowers, Randy Taplitz	2/20/2018
8.102	Supportive Care	Antimicrobial Prophylaxis for Immunosuppression in Adults With Cancer	Guideline Update	ASCO-IDS	Current	Christopher R. Flowers, Randy Taplitz	9/4/2018
8.11	Supportive Care	Central Venous Catheter Care	Guideline Update	n/a	Current		4/1/2013
8.12	Supportive Care	Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer	Guideline Update	n/a	Current	Anna Falanga, Gary Lyman	8/5/2019
8.14	Supportive Care	Patient-Physician Communication	De Novo Guideline	n/a	Current	Walter Baile, Tim Gilligan	9/11/2017
8.16	Supportive Care	ISOO/ASCO Guideline on Osteonecrosis of the Jaw	De Novo Guideline	ISOO-ASCO	Current	Noam Yarom, Charles Shapiro	7/22/2019
8.17	Supportive Care	ISOO/ASCO Guideline on Salivary Gland Hypofunction/Xerostomia	De Novo Guideline	ISOO-ASCO	Current	Siri Beier Jensen, Doug Peterson	7/20/2021
8.18	Supportive Care	ASCO/NCCN Immunotherapy Toxicities	De Novo Guideline	ASCO-NCCN	Current	Julie Brahmer (ASCO), John Thompson (NCI)	2/14/2018
8.19	Supportive Care	Integrative Therapies During and After Breast Cancer Treatment	Endorsement	SIO Endorsement	Current	Gary Lyman, Lorenzo Cohen	6/11/2018
8.20	Supportive Care	Management of Cancer Cachexia	De Novo Guideline	n/a	Current	Eric Roeland, Charles Loprinzi	5/20/2020
8.22	Supportive Care	Opioid Use During Active Cancer Treatment	De Novo Guideline		Current		
8.23	Supportive Care	Diet, Physical Activity and Weight Management During Cancer Treatment	De Novo Guideline		Current		
8.24	Supportive Care	Management of Dyspnea	De Novo Guideline		Current	David Hui, Margaret Campbell	2/22/2021
8.25	Supportive Care	Cannabis					
8.26	Supportive Care	Opioid Conversion					
8.27	Supportive Care	Vaccination					
9.08	Survivorship	Chronic Pain	De Novo Guideline	n/a	Current	Judith Paice, Eduardo Bruera, Michael Levy	7/25/2016
10.01		Chemo Assays					
12.04	Resource-Stratified	Global Palliative Care	De Novo Guideline	n/a	Current	Jim Cleary, Hibah Osman	5/8/2018
13.01	Geriatric Oncology	Evaluation and Management of Vulnerabilities in Older Patients With Cancer	De Novo Guideline	n/a	Under Review for Endorsement	William Dale, Arti Hurria, Supriya Mohile	5/21/2018
13.05	Neurooncology	Anticonvulsant Prophylaxis and Steroid Use in Adults with Metastatic Brain Tumors	Endorsement	CNS Endorsement	Current	Susan Chang, Michael Vogelbaum	3/18/2019
P.23	Supportive Care	Integration of Patient-Reported Outcomes in Cancer Care					
P.24	Supportive Care	Cancer and treatment related cognitive impairment					
P.25	Supportive Care	Addressing the needs of informal caregivers of people living with cancer					

**Survivorship**

Disease Site	Disease-Site Specific	Mix of cancer types
Breast	9.13	9.01 9.02 9.03 9.07 9.08 9.16 9.17 9.18 P.26 P.27
GI		
GU	9.09	
Gyn		
H&N	9.14	
Hem		
Neuro-onc		
Ophthalmic		
Pediatric	9.17	
Sarcoma		
Skin		
Thoracic		
Adult Cancers Only	9.05 9.12 9.15	

Blue Text: Current  
 Gray Italics: Archived  
 Green Text: Being Updated  
 Red Text: New Guideline in Development  
 Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
9.01	Survivorship	Fertility Preservation in Patients with Cancer	Guideline Update	n/a	Current	Alison Loren, Kutluk Oktay	4/5/2018
9.02	Survivorship	Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer	Adaptation	CCO Adaptation	In Progress	Barbara L. Andersen, Julia H. Rowland	4/14/2014
9.03	Survivorship	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer	Adaptation	CCO Adaptation	In Progress	Julienne E. Bower, Karen Mustian	4/14/2014
9.05	Survivorship	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors	De Novo Guideline	n/a	Current	Charles Loprinzi, Dawn Hershman	7/14/2020
9.07	Survivorship	Cardiac Dysfunction	De Novo Guideline	ASCO-ACC-AHA	Current	Saro Armenian, JB Durand	12/5/2016
9.08	Survivorship	Chronic Pain	De Novo Guideline	n/a	Current	Judith Paice, Eduardo Bruera, Michael Levy	7/25/2016
9.09	Survivorship	ACS's Prostate Cancer Survivorship Care Guideline	Endorsement	ACS Endorsement	Current	Matthew Resnick, David Penso	2/9/2015
9.12	Survivorship	Management of Osteoporosis in Survivors of Adult Cancers	De Novo Guideline	n/a	Current	Charles Shapiro, Joan Neuner	9/18/2019
9.13	Survivorship	Breast Cancer Survivorship Care Guideline	De Novo Guideline	ACS-ASCO	Current		12/7/2015
9.14	Survivorship	Head and Neck Cancer Survivorship Care Guideline	Endorsement	ACS Endorsement	Current	Larissa Nekhlyudov, Lillian Siu	2/27/2017
9.15	Survivorship	Interventions to Address Sexual Problems in People with Cancer	Adaptation	CCO Adaptation	Current	Julia Rowland, Jeanne Carter	12/11/2017
9.16	Survivorship	Integrative Approach to Cancer-Related Pain Management	De Novo Guideline	ASCO-SIO	Current		
9.17	Survivorship	Adolescent and Young Adult Survivorship	De Novo Guideline	n/a	In Progress		
9.18	Survivorship	Cancer During Pregnancy	De Novo Guideline	n/a	In Progress		
P.26	Survivorship	Management of Sleep Problems in Cancer Survivors					
P.27	Survivorship	Survivorship After Stem Cell Transplantation					

**Thoracic Cancer**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
Mesothelioma			6.08	6.08		6.08					
NSCLC		6.04	6.02 6.05	6.01 P.28	6.01 6.06 6.09 6.11 P.28	6.01 6.11 P.28	6.13 P.28	6.10			
SCLC		6.04	6.05	6.07	6.12 6.29	6.031 6.032 6.07 6.29	6.031 6.032 6.29	6.10			
Adenocarcinoma				P.30	P.30	P.30					

Blue Text: Current

Gray Italics: Archived

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
6.01	Thoracic	Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-III A Guideline Update	Guideline Update	ASCO-CCO	Current	Mark Kris, Laurie Gaspar	4/24/2017
6.02	Thoracic	Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients w/PCO		n/a	Archived		5/20/2011
6.031	Thoracic	Stage IV non-small-cell lung cancer (NSCLC)– non-driver alterations Guideline	Guideline Update	CCO	Current	Greg Masters, Nasser Hanna	1/28/2020
6.032	Thoracic	Stage IV non-small-cell lung cancer (NSCLC)– driver alterations Guideline	Guideline Update	CCO	Current	Greg Masters, Nasser Hanna	2/16/2021
6.04	Thoracic	The role of CT screening for Lung Cancer in clinical practice	De Novo Guideline	n/a	Archived		5/20/2012
6.05	Thoracic	CAP/IASLC/AMP Molecular Testing Guideline for Selection of Lung Cancer	Endorsement	CAP-IASLC-AMP E	Current	Navneet Narula, Gregory Kalemkeria	2/5/2018
6.06	Thoracic	Radiotherapy in locally advanced non-small cell lung cancer	Endorsement	ASTRO Endorseme	Current	Christopher G. Azzoli, Andrea Bezjak	5/5/2015
6.07	Thoracic	Treatment of SCLC	Endorsement	ACCP Endorsemer	Current	Giseppe Giaccone, Charles Rudin	9/8/2015
6.08	Thoracic	Treatment of Malignant Pleural Mesothelioma	De Novo Guideline	n/a	Current	Raffit Hassan, Hedy Kindler	1/18/2018
6.09	Thoracic	ASTRO Stereotactic Body Radiotherapy (SBRT) for Early Stage Non-small C	Endorsement	n/a	Current	Bryan Schneider, Brendon Stiles	11/6/2017
6.10	Thoracic	Lung Cancer Follow-Up	De Novo Guideline	n/a	Current	Bryan Schneider, Nasser Altorki	12/12/2019
6.11	Thoracic	Management of Stage III NSCLC	De Novo Guideline	n/a	Current		
6.12	Thoracic	Radiation Therapy for SCLC	Endorsement	ASTRO Endorseme	Current		1/27/2021
6.13	Thoracic	Systemic Therapy for SCLC	De Novo Guideline	ASCO-Ontario Hea	Current	Humera Khurshid, Greg Kalemkerian	10/11/2023
	Thoracic	Stage IV NSCLC Living Guideline			In Progress		
P.28	Thoracic	Management of Stage I Non-Small Cell Lung Cancer					
P.29	Thoracic	Duration of Systemic Therapy for Stage IV Lung Cancer					
P.30	Thoracic	Management of Multifocal Lung Adenocarcinoma					

**Melanoma**

Disease Site	Screening and Diagnosis			Treatment				Ongoing Care			
	Prevention and Promotion	Screening	Assessment, Pathology, and Staging	Surgery	Radiotherapy	Chemotherapy	Hormonal and Other Therapies	Surveillance and Follow-Up	Palliative Care	Supportive Care	Survivorship
All Disease Sites			7.01				7.02				

Blue Text: Current

*Gray Italics: Archived*

Green Text: Being Updated

Red Text: New Guideline in Development

Purple Text: Priority for new guideline (also labeled "P")

Project #	AG	Title	Type	Collaboration	Status	Co-Chairs	Date of Last Publication
7.01	Melanoma	Sentinel Lymph Node Biopsy for Melanoma	Guideline Update	ASCO-SSO	Current	Sandra L. Wong, Gary H. Lyman	12/12/2017
7.02	Melanoma	Systemic Therapy for Stage II-IV Melanoma	De Novo Guideline	n/a	Current	Rahul Seth, Pauline Funchain	8/14/2023